Discover KPV dosage trends, reconstitution volumes, and vial size preferences from anonymized WPA peptide calculator sessions.
KPV is a tripeptide fragment of alpha-MSH with potent anti-inflammatory properties, studied for applications including gut health and inflammatory conditions. This data reveals the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when setting up their KPV reconstitution protocol.
KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone — a three-amino-acid sequence (lysine-proline-valine, residues 11-13 of α-MSH) that the Lipton and Catania programs at the University of New Mexico and Sapienza University of Rome characterized across the 1990s and early 2000s as the structural region responsible for α-MSH's anti-inflammatory and immunomodulatory effects. The original observation was that the full α-MSH peptide produced both pigmentation effects (via the MC1 receptor) and a separate, distinct anti-inflammatory effect, and that the anti-inflammatory portion was preserved in the KPV fragment without any pigmentation activity — making it the cleanest possible chemical probe for the inflammation arm of the α-MSH biology.
KPV is an anti-inflammatory research peptide most often sourced for gut and skin protocols, frequently paired with BPC-157. It ships as a lyophilized powder you reconstitute with bacteriostatic water (and is sometimes used in oral or topical form).
KPV diffuses across cell membranes and acts intracellularly to inhibit NF-κB nuclear translocation and downstream pro-inflammatory cytokine transcription (TNF-α, IL-6, IL-8). Unlike α-MSH, KPV does not require melanocortin-receptor binding for its anti-inflammatory effect, which is consistent with its activity in MC1R-knockout models.
Pre-clinical work has focused on inflammatory bowel disease — orally and rectally administered KPV reduced colitis severity in DSS and TNBS mouse models and ex-vivo human colonic biopsies — and on atopic dermatitis and psoriasiform skin inflammation. No randomized human trials have been published; clinical interest persists in IBD adjuvant therapy and topical dermatology formulations.
KPV has a reported half-life of ~1 hour, and the dose intervals researchers model most often fall around once daily. Short half-life — each daily dose clears well before the next, so the working effect is essentially per-dose with no systemic accumulation. It is catalogued under Skin Peptides on WPA.
4,099 KPV reconstitution calculations have been logged by the WPA community. The most common dose entered is 500mcg (1,185 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (3,315 sessions). The most common dosing frequency is daily (7x/week) (439 logged protocols), followed by once weekly (165).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.